Time Restricted EATing (TREAT) Pilot Study

Sponsor
Columbia University (Other)
Overall Status
Completed
CT.gov ID
NCT03956290
Collaborator
(none)
64
1
1
18.4
3.5

Study Details

Study Description

Brief Summary

The TREAT Pilot is a 3 months open-label pilot study to examine the effect of restricting the duration of eating (Time Restricted EATing) in metabolically unhealthy adults with overweight or obesity. This pilot study will allow the investigator to collect preliminary data for the design of a larger study.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: TREAT pilot intervention
N/A

Detailed Description

Disruption of the circadian rhythm, caused by aging, obesity, shift work, or prolonged daily eating duration into hours normally reserved for sleep, is a recognized risk factor for impaired metabolism and cardiovascular disease risk. Mice with disrupted clock gene have dysmetabolism. Restricting the eating window in these mice improves their metabolism.

Data will be collected to examine the feasibility and effect of a lifestyle intervention, aiming to reduce body weight in metabolically unhealthy individuals with overweight and obesity. The TREAT pilot study employs the use of mobile application to document eating behavior, when, what and how much people eat. In addition, the participants will receive reminders and complete in-person study visits to monitor their eating and sleeping schedule.

Study Design

Study Type:
Interventional
Actual Enrollment :
64 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Time Restricted EATing (TREAT) Pilot Study
Actual Study Start Date :
Jul 1, 2019
Actual Primary Completion Date :
Jan 11, 2021
Actual Study Completion Date :
Jan 11, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: TREAT pilot study

Metabolically unhealthy overweight or obese potential participants who pass an in-person screen will enroll in a 2-week run-in period when they will use the app, to assess meal patterns under habitual living conditions.

Behavioral: TREAT pilot intervention
Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
Other Names:
  • TREAT
  • Outcome Measures

    Primary Outcome Measures

    1. Percentage of participants logging [3 months]

      To measure the usage of app by recording the total number of days the participants logged in during study. Reported in percentage from 0 to 100% of time in use.

    2. Percentage of patients who reduced eating duration by 4 hours [3 months]

      Change in eating duration from pre- to post-intervention will be calculated in from data collected in hours spent eating

    Secondary Outcome Measures

    1. % weight loss achieved post-intervention [Baseline to 3 months]

      Weight will be recorded and compared at baseline and 3 months.

    2. Average time in duration of overnight fasting [3 months]

      Hours of overnight fasting will be recorded.

    3. Average time in sleep duration [3 months]

      Hours of sleep each night will be recorded.

    4. Adherence to using the app [3 months]

      Participants that completed daily food logs in app, and have days completed with correct eating duration.

    5. % of participants who achieve ≥ 5% weight loss [Baseline to 3 months]

      Weight will be recorded and compared at baseline and 3 months.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    45 Years to 73 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • age: 45-73y old

    • overweight or obesity with BMI ≥25.0 and ≤35.0 kg/m2

    • pre-diabetes or diabetes only diet controlled (HbA1c <7%)

    • elevated Blood Pressure (BP) 120-129/<80 mmHg or stage 1 high BP 130-139/80-89 mmHg, with clinical Atherosclerotic Cardiovascular Disease (ASCVD) or estimated 10-y Cardiovascular Disease (CVD) risk <10%

    • having LDL cholesterol <150mg/dl

    • no known sleep, psychiatric or food intake disorders

    • in possession of a smart phone

    • English-speaking

    • must live in New York city geographical area and not have planned travel schedule interfering with the study

    Exclusion Criteria:
    • history or clinical evidence of condition that affect sleep

    • significant organ system dysfunction/disease: diabetes, severe pulmonary, kidney or cardiovascular disease, and any evidence of active illness (e.g., fever)

    • history of seizure disorder

    • being on medications for diabetes, hypertension or dyslipidemia

    • previous bariatric surgery

    • history or current significant psychiatric disorder

    • use dietary supplements and/or medications known to affect sleep, circadian rhythms or metabolic function

    • smoking tobacco or using illegal or recreational drugs

    • consume excessive alcohol (women: >14 drinks/wk; men: >21 drinks/wk)

    • consume large amounts of caffeine daily (>2 cups of coffee or 8 oz caffeinated drinks per day)

    • participate in intense exercise (causing heavy breathing and sweating, such as jogging) >2 d/wk for ≥35 min or moderate exercise (e.g., brisk walking) for >150 min/wk

    • shift work

    • extreme early and late chronotypes

    • unwilling/unable to provide informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Obesity Nutrition Research Center New York New York United States 10032-3702

    Sponsors and Collaborators

    • Columbia University

    Investigators

    • Principal Investigator: Blandine Laferrère, M.D., PhD., Columbia University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Blandine Laferrere, Professor of Medicine, Columbia University
    ClinicalTrials.gov Identifier:
    NCT03956290
    Other Study ID Numbers:
    • AAAS3053
    First Posted:
    May 20, 2019
    Last Update Posted:
    Jul 19, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Blandine Laferrere, Professor of Medicine, Columbia University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 19, 2021